Robust Hepatic Gene Silencing for Functional Studies Using Helper-Dependent Adenoviral Vectors

被引:12
|
作者
Ruiz, Rafaela [1 ,2 ]
Witting, Scott R. [1 ]
Saxena, Romil [3 ]
Morral, Nuria [1 ,4 ]
机构
[1] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA
[2] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA
[3] Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
[4] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA
关键词
FULL-LENGTH DYSTROPHIN; CRE-MEDIATED EXCISION; IN-VIVO; VIRAL GENES; RECOMBINANT ADENOVIRUSES; SINGLE INJECTION; CELL-LINES; MICE; EXPRESSION; LIVER;
D O I
10.1089/hum.2008.081
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
RNA interference is currently envisioned as the basis of gene function and drug target validation studies. This novel technology has the advantage of providing a remarkably faster tool for gene silencing than traditional transgenic animal methodologies. In vivo administration of short interfering RNA (siRNA) typically results in reduced target gene expression for approximately 1 week. Viral vectors offer the possibility to express constitutive levels of short hairpin RNA (shRNA) so that the effects of knocking down the target gene can be studied for a few weeks, rather than a few days. Helper-dependent vectors have a significant advantage over previous generations of adenoviral vectors because of their much higher cloning capacity, potential for long-term transgene expression, and enhanced safety profiles on administration in vivo. Therefore, this advanced type of vector is an excellent tool to carry out in vivo studies directed at constitutive expression of shRNA. Here we show it is possible to obtain more than 90% target gene knockdown in an animal model of type 2 diabetes for several weeks, thereby consolidating this technology as an alternative to generating liver-specific knockout animals.
引用
收藏
页码:87 / 94
页数:8
相关论文
共 50 条
  • [41] Progress towards the clinical application of helper-dependent adenoviral vectors for liver and lung gene therapy
    Brunetti-Pierri, Nicola
    Ng, Philip
    [J]. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2006, 8 (05) : 446 - 454
  • [42] PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile
    Croyle, MA
    Le, HT
    Linse, KD
    Cerullo, V
    Toietta, G
    Beaudet, A
    Pastore, L
    [J]. GENE THERAPY, 2005, 12 (07) : 579 - 587
  • [43] Phenotypic correction of ornithine transcarbamylase deficiency using tow dose helper-dependent adenoviral vectors
    Brunetti-Pierri, Nicola
    Clarke, Christian
    Mane, Viraj
    Palmer, Donna J.
    Lanpher, Brendan
    Sun, Qin
    O'Brien, William
    Lee, Brendan
    [J]. JOURNAL OF GENE MEDICINE, 2008, 10 (08): : 890 - 896
  • [44] Improved vascular gene transfer with a helper-dependent adenoviral vector
    Wen, S
    Graf, S
    Massey, PG
    Dichek, DA
    [J]. CIRCULATION, 2004, 110 (11) : 1484 - 1491
  • [45] Insulin-gene therapy of diabetes in mice by glucose-regulated helper-dependent adenoviral vectors
    Corbella, P
    Perani, L
    Mingozzi, F
    Recchia, A
    Mavilio, F
    Roncarolo, MG
    Falqui, L
    [J]. MOLECULAR THERAPY, 2003, 7 (05) : S79 - S80
  • [46] Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy
    Ranmal Avinash Bandara
    Ziyan Rachel Chen
    Jim Hu
    [J]. Cell & Bioscience, 11
  • [47] Helper-Dependent Adenoviral Vectors for Liver-Directed Gene Therapy of Primary Hyperoxaluria Type 1
    Castello, Raffaele
    DAria, Stefania
    Borzone, Roberta
    Piccolo, Pasquale
    Annunziata, Patrizia
    Brunetti-Pierri, Nicola
    [J]. MOLECULAR THERAPY, 2013, 21 : S139 - S139
  • [48] Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1
    Castello, R.
    Borzone, R.
    D'Aria, S.
    Annunziata, P.
    Piccolo, P.
    Brunetti-Pierri, N.
    [J]. GENE THERAPY, 2016, 23 (02) : 129 - 134
  • [49] Evaluating the tropism of chimeric helper-dependent adenoviral vectors for delivery of large genes
    Wiley, Luke A.
    Burnight, Erin R.
    Ochoa, Dalyz
    Collins, Malia M.
    Varzavand, Katayoun
    Stone, Edwin M.
    Mullins, Robert F.
    Tucker, Budd A.
    Han, Ian
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [50] PEGylated helper-dependent adenoviral vector for gene therapy of Hyperlipidemias
    Leggiero, E.
    Astone, D.
    Wonganan, P.
    Mazzaccara, C.
    Labruna, G.
    Sacchetti, L.
    Salvatore, F.
    Croyle, M.
    Pastore, L.
    [J]. HUMAN GENE THERAPY, 2010, 21 (10) : 1400 - 1400